GeneSys Biologics was established in Nov 2014 by a group of like-minded individuals with strong global experience in development of biosimilars. 

A science-based biosimilar company with the vision of becoming one of the leading global biopharmaceutical companies in the world. 

GeneSys aims to expand market access across the globe by providing affordable and high quality biosimilars.

GeneSys Biologics was founded with a mission to serve large diabetic patient population across the world with most affordable insulins. They specialize in making insulin biosimilars with a patient-first approach, taking a sincere shot at solving the world’s largest decades old problem. We aim to make an impactful difference in building healthy society.